DOD Lung Cancer, Idea Development Award | HT9425 23 LCRP IDA

Opportunity Information: Apply for HT9425 23 LCRP IDA

The FY23 Department of Defense Lung Cancer Research Program (LCRP) Idea Development Award (Funding Opportunity Number HT9425 23 LCRP IDA; CFDA 12.420) is designed to push forward early-stage, conceptually new lung cancer research ideas that are not yet fully established but could open up important new directions. The program is explicitly geared toward high-risk, high-reward projects where the main value is the potential to generate impactful data, uncover new mechanisms, or create fresh investigative avenues that ultimately help accelerate progress toward reducing deaths and suffering from lung cancer. While the opportunity is broadly open in terms of applicant types (unrestricted eligibility, with any specific nuances contained in the full eligibility section of the announcement), the research focus must be clearly tied to lung cancer. Proposals that are only about mesothelioma are not allowed under this mechanism, so applicants need to ensure their aims and framing are centered on lung cancer rather than mesothelioma-only questions.

A central expectation is that applicants propose a well-formulated and testable hypothesis backed by strong scientific rationale. This is not meant to fund vague exploratory concepts without a clear logic chain; instead, the award aims to support bold ideas that are still early but can be approached with rigorous hypothesis-driven work. Even though the award supports early development, preliminary data are still required to demonstrate feasibility of the hypothesis and the planned approach. Importantly, those feasibility data do not have to come directly from lung cancer studies, meaning applicants may leverage convincing prior work from related systems, methods development, platform validation, or other disease contexts, as long as the evidence credibly supports the ability to execute the proposed lung cancer-focused work.

The mechanism includes a specific emphasis on supporting New Investigators, defined here as independent investigators who are within 10 years of their first faculty appointment (or an equivalent career milestone). New Investigators are intended to compete in a separate category from Established Investigators, with peer and programmatic review conducted separately for the two groups. This separation is meant to reduce the structural disadvantage early-career investigators can face when competing directly against long-established labs with extensive track records. For New Investigators in particular, the program strongly encourages building collaborations with researchers who have direct lung cancer expertise and/or other capabilities that meaningfully strengthen the project. The application needs to clearly explain how the collaboration fills gaps in the PI's experience and improves the team’s ability to answer the research question, rather than listing collaborators in a superficial way.

Reviewers will be looking for two defining qualities: innovation and impact. Innovation, in this context, means more than incremental improvement; it can include introducing a new paradigm, challenging a prevailing model, reframing a longstanding problem through a different lens, or using unusually creative approaches that are not commonly applied in the field. Impact refers to the realistic potential for the work to drive major advancements and measurably accelerate progress toward eliminating lung cancer mortality and suffering. Applicants carry the burden of making these points explicit. The proposal should spell out, in plain terms, what is truly new about the idea, why it matters, and how it could change what researchers or clinicians can do in the lung cancer space. The announcement also requires that applicants address relevance to Military Health System (MHS) beneficiaries, meaning the narrative should connect the work to the needs, risks, exposures, care realities, or health outcomes pertinent to service members, veterans, and other MHS-covered populations. Even if the project is not expected to produce immediate clinical changes, the application should still articulate how the results could ultimately benefit patients with lung cancer or shift the trajectory of lung cancer research in a way that matters to patient outcomes.

Administratively, this opportunity is offered by the Department of Defense, Department of the Army, through USAMRAA, and it supports projects via cooperative agreements and grants under the science and technology/research and development activity category. The announcement lists an expected total of about 10 awards. The original FY23 posting indicates a creation date of February 16, 2023, and an original closing date of August 3, 2023, and the listed award ceiling is shown as 0 in the summarized record (which often means applicants should rely on the full announcement text for definitive budget limits, caps by category, and cost guidance). The bottom line is that this award is aimed at researchers with strong, testable, feasibility-supported concepts that are genuinely innovative, clearly positioned for high impact, and convincingly relevant to lung cancer outcomes, including for Military Health System beneficiaries, while explicitly excluding mesothelioma-only proposals.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Lung Cancer, Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Feb 16, 2023.
• Applicants must submit their applications by Aug 03, 2023. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 10 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for HT9425 23 LCRP IDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: